Komori
Management Planning190AChordia Therapeutics Inc.Pharmaceuticals

Disclosure of Matters Concerning Business Plans and Growth Potential

Previously, the company assumed that it would initiate a Phase 2 trial in mid-2027 and submit an application for approval in late 2028 under a company-led development model, but it has withdrawn that timing. Going forward, it has revised its policy to decide whether to proceed through in-house development, co-development or out-licensing based on the results of the expanded cohort and the outlook for financing.

Worth reading
37Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

Items stated in the management plan

Partially revised
2030 VisionPlan period Start year Not disclosed / Final year 2030
What happened to the previous planPhase 2 start: mid-2027; application for approval: late 2028 → Not disclosed
Key initiatives
01Expansion of clinical trials (rogocekib)
02Focus on rare cancers
03Establish value through clinical data and commercialize in the optimal format
04Leverage AMED GRiT to consider a Japan-participating US-Japan joint clinical trial starting with the AE cohort
05Consider a Phase 2 clinical trial plan based on the results of the expanded cohort
06Determine how to proceed toward obtaining approval from among in-house development, co-development and out-licensing
07Consider realizing value through a partnership
08Work with partners
Plan assumptionsEstimated potential patient population for second-line and later AML treatment: approximately 18,750 people, Assumed drug price: ¥40,000 or ¥90,000 per day, Assumed treatment duration: 270 days, The market size estimate is the company's own estimate based on external research materials and other sources, and may differ materially from the actual market size., The development timeline may change depending on development progress, discussions with regulatory authorities, the status of partnership discussions and external conditions.
Size of the Target MarketAML treatment market (8 major countries): $2.32 billion in 2022, forecast to reach $3.68 billion in 2032. Decline in existing drugs: $360 million; sales of new drugs: $1.72 billion. Source: GlobalData, “Acute Myeloid Leukemia (AML): Opportunity Assessment and Forecast” (published in 2023), Potential market size for second-line and later AML treatment: approximately ¥200 billion to ¥400 billion. The company's own estimate based on external research materials and other sources, Potential market size for ovarian cancer: ¥100 billion or more. The company's own estimate
Risks identified by the company
Risk that the progress, timing or results of the clinical trial will differ from expectations
Risk that the progress, timing or results of new drug approval will differ from expectations
Risk that the development timeline will change due to development progress, discussions with regulatory authorities, the status of partnership discussions or external conditions
Uncertainty regarding whether future agreements will be signed, as well as their timing and terms
The initial clinical trial results are based on a small number of cases and require confirmation in additional cases
Risk of being unable to identify the patients likely to benefit
Possibility that the estimated market size will differ materially from the actual market size
Reason for revision or withdrawal

To determine the next development strategy based on the evaluation of the expanded cohort. Based on the funding required for development and the outlook for raising those funds, determine how to proceed toward obtaining approval from among in-house development, co-development and out-licensing.

Items stated in the management plan
ItemDetails
Plan name2030 Vision
Plan periodStart year Not disclosed / Final year 2030
Progress against the planPartially revised
Plan assumptionsEstimated potential patient population for second-line and later AML treatment: approximately 18,750 people, Assumed drug price: ¥40,000 or ¥90,000 per day, Assumed treatment duration: 270 days, The market size estimate is the company's own estimate based on external research materials and other sources, and may differ materially from the actual market size., The development timeline may change depending on development progress, discussions with regulatory authorities, the status of partnership discussions and external conditions.
Key initiativesExpansion of clinical trials (rogocekib), Focus on rare cancers, Establish value through clinical data and commercialize in the optimal format, Leverage AMED GRiT to consider a Japan-participating US-Japan joint clinical trial starting with the AE cohort, Consider a Phase 2 clinical trial plan based on the results of the expanded cohort, Determine how to proceed toward obtaining approval from among in-house development, co-development and out-licensing, Consider realizing value through a partnership, Work with partners
Results under the previous planPhase 2 start: mid-2027; application for approval: late 2028 → Not disclosed
Reason for revision or withdrawalTo determine the next development strategy based on the evaluation of the expanded cohort. Based on the funding required for development and the outlook for raising those funds, determine how to proceed toward obtaining approval from among in-house development, co-development and out-licensing.
Size of the Target MarketAML treatment market (8 major countries): $2.32 billion in 2022, forecast to reach $3.68 billion in 2032. Decline in existing drugs: $360 million; sales of new drugs: $1.72 billion. Source: GlobalData, “Acute Myeloid Leukemia (AML): Opportunity Assessment and Forecast” (published in 2023), Potential market size for second-line and later AML treatment: approximately ¥200 billion to ¥400 billion. The company's own estimate based on external research materials and other sources, Potential market size for ovarian cancer: ¥100 billion or more. The company's own estimate
Risks identifiedRisk that the progress, timing or results of the clinical trial will differ from expectations, Risk that the progress, timing or results of new drug approval will differ from expectations, Risk that the development timeline will change due to development progress, discussions with regulatory authorities, the status of partnership discussions or external conditions, Uncertainty regarding whether future agreements will be signed, as well as their timing and terms, The initial clinical trial results are based on a small number of cases and require confirmation in additional cases, Risk of being unable to identify the patients likely to benefit, Possibility that the estimated market size will differ materially from the actual market size
Items this document does not state (16)
Sales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsDate of board resolutionPublication date

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To determine the next development strategy based on the evaluation of the expanded cohort. Also, to determine how to proceed toward obtaining approval based on the funding required for development and the outlook for raising those funds.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Disclosure of Matters Concerning Business Plans and Growth Potential | Chordia Therapeutics Inc. (190A) timely disclosure | Komori